Cosmo First Ltd

Q4 FY25 Earnings Call Analysis

Industrial Products

Full Stock Analysis
fundraise: Nocapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
💰

fundraise

Any current/future new fundraising through debt or equity?

- The company is committed to completing around INR400 crores of CAPEX over the next 1.5 years, primarily on BOPP and CPP lines. - Management does not mention any plans for new equity fundraising. - The current net debt stood at approximately INR600 crores as of December 2023. - The company expects total debt to remain around INR900-950 crores, with net debt to EBITDA not exceeding 3 times. - Further CAPEX beyond the committed INR400 crores will be dependent on market conditions; if the situation remains unchanged, no additional CAPEX or debt is planned. - The company is generating cash from operations, which supports the existing and near-term debt serviceability. - Overall, no new fundraising plans through debt or equity are explicitly stated, with a focus on managing current commitments and maintaining a comfortable debt level.
🏗️

capex

Any current/future capex/capital investment/strategic investment?

- The company has committed close to INR400 crores of CAPEX over the next 1.5 years, primarily for BOPP and CPP lines. - No new BOPET capacity is planned; focus remains on Specialty products in BOPET. - The new BOPP line will increase production capacity by 45%-50% by March 2025. - Investments include infrastructure for capacitor films (INR23 crores invested, INR15 crores remaining for second line). - Rigid Packaging line investment totals close to INR100 crores (fully invested). - The company is focusing new investments on growth areas outside core films like window films, Rigid Packaging, Speciality Chemicals, and Zigly. - Petcare vertical (Zigly) is operational with operational expenses rather than capital intensive. - Future film business investments will focus on value addition like coatings and special metallization. - No plans to delay ongoing CAPEX, despite current margin pressures; expansion expected to support future growth. Overall CAPEX guidance: INR400 crores committed; no major new projects planned until market improves.
📊

revenue

Future growth expectations in sales/revenue/volumes?

- FY 2025 topline expected to stay close to INR 3,000 crores plus or minus some percentage, but exact sales mix is difficult to project due to raw material price fluctuations and margin variability (Page 15-16). - New capacity additions like CPP line (~25,000 metric tons) and thermoforming capacity metallizers are expected to run close to full utilization next year, supporting topline growth (Page 15). - Specialty and semi-specialty product segments have a growth pipeline; management aims to scale new adjacent businesses like window films, rigid packaging, chemicals, and pet care (Zigly), which are large and expanding markets (Page 16). - Capacity expansions in BOPP and CPP lines will increase production capacity by 45%-50% by March 2025 and are expected to rationalize production costs by 3-5% (Page 4). - Medium-term expectation to normalize margins and profitability as demand-supply balance improves (Page 14-16). - New businesses like specialty chemicals and Zigly targeted to become meaningful contributors in coming years (Page 8, 16).
📈

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Speciality chemical subsidiary expected to deliver double-digit EBITDA with high teens margin from FY 2025, driving future growth. - New businesses like Cosmo Speciality chemicals and Rigid Packaging anticipated to start earning money by next year. - Zigly (petcare vertical) currently incurring losses (~INR30 crores EBITDA loss in FY 2024) but growing month-on-month; losses expected to continue next year but reducing. - Capacitor metallizer business expected to generate close to INR40 crores annual sales with double-digit EBITDA from FY 2025. - Bottom line improvement expected from cost rationalization initiatives, adding INR45-50 crores annually from FY 2025. - BOPET speciality portfolio progressing; margins expected to normalize and breakeven in 3-4 quarters despite current overcapacity. - BOPP segment margins expected to improve within 12 months as demand-supply balances. - Overall, business growth driven by adjacent sectors and speciality portfolios, with a medium-term normalization of margins and profitability.
📋

orderbook

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention the current or expected order book or pending orders figures for Cosmo First Limited. However, relevant insights include: - The company is progressing with CAPEX of around INR400 crores mainly for BOPP and CPP lines, expected to increase production capacity by 45-50% by March 2025. - There is no indication of major additional CAPEX or major new projects beyond the current pipeline in the next 2-3 years. - Specialty films and adjacent businesses like Rigid Packaging, Speciality Chemicals, and Zigly (Petcare) are areas of ongoing investment and growth. - Demand-supply balance is expected to improve in 12 months for BOPP, supporting ramp-up of new capacities. - No explicit order book or pending order numbers were disclosed in the call or transcript.